Filing Flows › Recursion Pharmaceuticals (RXRX) › Q2 2026 › vs Q2 2025
Recursion Pharmaceuticals (RXRX) Q2 2026 vs Q2 2025 (year over year)
Recursion Pharmaceuticals's revenue fell $11.6M (-60%) from $19.2M in Q2 2025 to $7.7M in Q2 2026. The biggest changes: Operating revenue −$11.8M (-62%); Grant revenue +$247K (+206%).
Recursion Pharmaceuticals, Q2 2026: revenue $7.7M (-60% year over year), net loss $131M, operating cash flow −$106M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Operating revenue | $7.3M | $19.1M | −$11.8M | -62% |
| Grant revenue | $367K | $120K | $247K | +206% |
| Revenue | $7.7M | $19.2M | −$11.6M | -60% |
| Other income, net | $4.0M | $4.3M | −$368K | -8% |
| Income tax benefit | $1K | $0 | $1K | — |
| Net loss | $131M | $172M | −$40.9M | -24% |
| Costs & expenses | $143M | $195M | −$52.8M | -27% |
| Operating costs | $143M | $195M | −$52.8M | -27% |
| Cost of revenue | $11.5M | $20.2M | −$8.7M | -43% |
| Research & development | $89.6M | $129M | −$39.0M | -30% |
| General & admin | $41.5M | $46.7M | −$5.1M | -11% |
| Operating cash sources | $144M | $126M | $17.2M | +14% |
| Depreciation & amortization | $18.2M | $23.8M | −$5.7M | -24% |
| Share-based compensation | $19.5M | $26.2M | −$6.7M | -25% |
| Cash used in operations | $106M | $76.4M | $29.5M | +39% |
| Net loss absorbed | $131M | $172M | −$40.9M | -24% |
| Working capital & other | $12.6M | −$45.5M | $58.1M | — |
Questions
How much did Recursion Pharmaceuticals's revenue grow year over year in Q2 2026?
Recursion Pharmaceuticals's revenue fell $11.6M (-60%) from $19.2M in Q2 2025 to $7.7M in Q2 2026.
What drove Recursion Pharmaceuticals's revenue change in Q2 2026?
Operating revenue −$11.8M (-62%); Grant revenue +$247K (+206%).